This comes as the global shortage for the drug, Glucagon-Like Peptide-Receptor Agonists or GLP1 intended to treat type 2 diabetes, continues.

The drug is considered a valuable addition to diabetes management, promoting better blood sugar control. 

Social media Influencers in particular have marketed the drug as a weightloss miracle and those desperate to shed extra kilos have hounded the global market. Murphy elaborates..

“I think we have to appeal to the healthcare providers to say please keep it for the registered indication which is type 2 diabetes. Chances are we will see the registered indication for weight loss coming in the future. There are other medications in development in the same group.

The whole space will change in the next year.”

--ChannelAfrica--